Admetsys

Diabetes is the fastest-growing cause of inpatient and surgical care costs in the world. Worldwide spending on diabetic care already exceeds $400 billion annually, with 43% of these costs coming from hospital care in Europe and the United States.
Over 40% of patients admitted to hospital are now at diabetic risk. Despite this, techniques for controlling glucose levels in hospitalized patients have remained unchanged for nearly three decades, and are too imprecise, labor-intensive, and coarsely implemented to address the growing need.
Admetsys has developed the first fully-automated glucose control system specifically for the needs of hospital and surgical care. The system attaches to a patient’s intravenous line, and automatically measures blood glucose concentration in real time with no blood loss. From this, it creates an adaptive, computational model of each patient’s metabolism, and infuses precisely-optimized, counterbalancing treatment—insulin to reduce high glycemic levels and glucose to raise and support falling levels.
Proper control of blood glucose levels and avoidance of harmful low levels saves lives (34% mortality reduction), decreases complications (by 40–50% over numerous co-morbidities), and speeds recovery (by 1.8 days in critical care patients). Foremost, this is a fundamental standard of care issue, increasingly cited by regulatory and standards bodies. Understanding of this need is becoming a key financial driver for hospitals as well, with impact both on revenue (from outcome-based reimbursement) and cost savings (independently shown to be $7,500+ per patient).